224 related articles for article (PubMed ID: 22404148)
1. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
2. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu XJ; Nowak B; Wang YQ; Plunkett W
Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
4. New nucleoside analogs in the treatment of solid tumors.
Szafraniec SI; Stachnik KJ; Skierski JS
Acta Pol Pharm; 2004; 61(4):297-305. PubMed ID: 15575597
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine: a critical nucleoside for cancer therapy.
Gesto DS; Cerqueira NM; Fernandes PA; Ramos MJ
Curr Med Chem; 2012; 19(7):1076-87. PubMed ID: 22257063
[TBL] [Abstract][Full Text] [Related]
7. Nucleoside analogues in the treatment of haematological malignancies.
Johnson SA
Expert Opin Pharmacother; 2001 Jun; 2(6):929-43. PubMed ID: 11585009
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF; Reitz J
Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804
[TBL] [Abstract][Full Text] [Related]
9. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
10. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Faderl S; Gandhi V; Kantarjian HM
Curr Opin Hematol; 2008 Mar; 15(2):101-7. PubMed ID: 18300755
[TBL] [Abstract][Full Text] [Related]
11. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.
Balboni B; El Hassouni B; Honeywell RJ; Sarkisjan D; Giovannetti E; Poore J; Heaton C; Peterson C; Benaim E; Lee YB; Kim DJ; Peters GJ
Expert Opin Investig Drugs; 2019 Apr; 28(4):311-322. PubMed ID: 30879349
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
14. Sapacitabine in the treatment of acute myeloid leukemia.
Norkin M; Richards AI
Expert Rev Anticancer Ther; 2015; 15(11):1261-6. PubMed ID: 26523431
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
Rizzuto I; Ghazaly E; Peters GJ
Pharmacogenomics; 2017 Jun; 18(9):911-925. PubMed ID: 28594276
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer.
Sandler A; Ettinger DS
Oncologist; 1999; 4(3):241-51. PubMed ID: 10394591
[TBL] [Abstract][Full Text] [Related]
17. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of sugar-modified cytosine nucleosides.
Matsuda A; Sasaki T
Cancer Sci; 2004 Feb; 95(2):105-11. PubMed ID: 14965358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
